Neurocrine Biosciences (LTS:0K6R) Accounts Payable: $142 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0K6R Neurocrine Biosciences Inc LTS:0K6R
94 GF Score
Price $166.30
GF Value $192.89
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Accounts Payable?

Neurocrine Biosciences LTS:0K6R -7.69% 94 Accounts Payable is $142 Mil as of Jun. 2026. GuruFocus rates LTS:0K6R with a GF Score™ of 94/100 and a GF Value™ of $192.89 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Neurocrine Biosciences's Accounts Payable for the quarter that ended in Jun. 2026 was $142 Mil.

Neurocrine Biosciences's quarterly Accounts Payable increased from Dec. 2025 ($105 Mil) to Mar. 2026 ($120 Mil) and increased from Mar. 2026 ($120 Mil) to Jun. 2026 ($142 Mil).

Neurocrine Biosciences's annual Accounts Payable declined from Dec. 2023 ($133 Mil) to Dec. 2024 ($100 Mil) but then increased from Dec. 2024 ($100 Mil) to Dec. 2025 ($105 Mil).

Neurocrine Biosciences Accounts Payable Related Terms

Neurocrine Biosciences Accounts Payable Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Accounts Payable Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.50 67.30 133.30 99.90 104.90

Neurocrine Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 104.60 119.90 104.90 120.00 142.00
LTS:0K6R
94GF Score
Neurocrine Biosciences Inc LTS:0K6R
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $142 Mil mean?
Neurocrine Biosciences (LTS:0K6R) has a Accounts Payable of $142 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Neurocrine Biosciences and its competitors.
Is Neurocrine Biosciences' Accounts Payable too high?
Neurocrine Biosciences' current Accounts Payable is $142 Mil. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Accounts Payable compare to VTRS and UTHR?
Neurocrine Biosciences' Accounts Payable of $142 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Neurocrine Biosciences and its competitors. Neurocrine Biosciences's current Accounts Payable is $142 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (LTS:0K6R) is currently considered Modestly Undervalued. The stock's GF Value™ is $192.89, compared to a current price of $166.30 — trading 13.8% below its estimated fair value. The current Accounts Payable is $142 Mil. Neurocrine Biosciences' overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Neurocrine Biosciences (LTS:0K6R), the current Accounts Payable is $142 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (LTS:0K6R) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of $166.30 is trading 13.8% below its estimated GF Value™ of $192.89. GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.

Key valuation signals for LTS:0K6R:

  • Accounts Payable: $142 Mil
  • GF Value™: $192.89 vs. price of $166.30 (13.8% below fair value)
  • GF Score™: 94/100 with 4 warning signs

No single metric tells the full story. See the LTS:0K6R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score

Get the complete analysis for LTS:0K6R

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$166.30
Price
$192.89
GF Value